Advanced therapeutic modalities in hepatocellular carcinoma: Novel insights.
gene therapy
hepatocellular carcinoma
immune checkpoint inhibitors
immunotherapy
molecular-targeted therapy
radionuclide therapy
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
28
07
2021
received:
28
04
2021
accepted:
04
08
2021
pubmed:
24
8
2021
medline:
22
2
2022
entrez:
23
8
2021
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC), the most common type of liver cancer, is usually a latent and asymptomatic malignancy caused by different aetiologies, which is a result of various aberrant molecular heterogeneity and often diagnosed at advanced stages. The incidence and prevalence have significantly increased because of sedentary lifestyle, diabetes, chronic infection with hepatotropic viruses and exposure to aflatoxins. Due to advanced intra- or extrahepatic metastasis, recurrence is very common even after radical resection. In this paper, we highlighted novel therapeutic modalities, such as molecular-targeted therapies, targeted radionuclide therapies and epigenetic modification-based therapies. These topics are trending headlines and their combination with cell-based immunotherapies, and gene therapy has provided promising prospects for the future of HCC treatment. Moreover, a comprehensive overview of current and advanced therapeutic approaches is discussed and the advantages and limitations of each strategy are described. Finally, very recent and approved novel combined therapies and their promising results in HCC treatment have been introduced.
Identifiants
pubmed: 34423899
doi: 10.1111/jcmm.16875
pmc: PMC8435417
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
8602-8614Informations de copyright
© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Hepatology. 2000 Mar;31(3):606-14
pubmed: 10706550
Int J Cancer. 2019 Aug 15;145(4):1111-1124
pubmed: 30719701
Cell. 1978 Oct;15(2):393-403
pubmed: 214238
Cancer Lett. 2012 Dec 31;327(1-2):5-15
pubmed: 22542631
Br J Cancer. 2020 May;122(11):1630-1637
pubmed: 32238921
Cancer Res. 1968 Sep;28(9):1908-14
pubmed: 5676741
Clin Transl Med. 2019 May 6;8(1):13
pubmed: 31056726
J Exp Clin Cancer Res. 2019 Sep 9;38(1):396
pubmed: 31500650
Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):681-700
pubmed: 26484443
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Mol Med Rep. 2016 Mar;13(3):2124-34
pubmed: 26783185
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):548-560
pubmed: 32164877
Pharmacol Res. 2020 Oct;160:105070
pubmed: 32659429
Cell Physiol Biochem. 2018;47(2):721-734
pubmed: 29794465
Clin Transl Oncol. 2019 Jun;21(6):702-712
pubmed: 30387047
Cancers (Basel). 2019 Jul 30;11(8):
pubmed: 31366113
Cancers (Basel). 2019 Jul 15;11(7):
pubmed: 31311170
Mol Ther. 2018 Feb 7;26(2):366-378
pubmed: 29339014
Clin Cancer Res. 2006 May 1;12(9):2817-25
pubmed: 16675576
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Nature. 2004 May 27;429(6990):457-63
pubmed: 15164071
Acta Pharmacol Sin. 2015 Oct;36(10):1191-9
pubmed: 26073325
Cancer Lett. 2011 Nov 1;310(1):61-8
pubmed: 21757290
Nature. 2015 Oct 1;526(7571):55-61
pubmed: 26432244
Int J Cancer. 2011 Feb 15;128(4):887-96
pubmed: 20473887
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Int J Mol Sci. 2019 Mar 05;20(5):
pubmed: 30841513
Clin Cancer Res. 2017 Jan 15;23(2):478-488
pubmed: 27535982
Cancer Lett. 2016 Jun 28;376(1):95-103
pubmed: 26945965
Cancer Chemother Pharmacol. 2009 Mar;63(4):605-13
pubmed: 18521605
Transl Oncol. 2017 Apr;10(2):132-141
pubmed: 28129580
J Hematol Oncol. 2018 Mar 15;11(1):39
pubmed: 29544515
Oncogene. 2018 May;37(18):2456-2468
pubmed: 29449693
Immunol Lett. 2013 Feb;150(1-2):116-22
pubmed: 23261718
Oncol Rep. 2015 Nov;34(5):2238-50
pubmed: 26352599
Cells. 2020 Jan 27;9(2):
pubmed: 32012725
Lancet Oncol. 2020 Apr;21(4):571-580
pubmed: 32112738
Front Oncol. 2019 Jan 21;9:19
pubmed: 30719425
Value Health. 2013 Sep-Oct;16(6 Suppl):S4-9
pubmed: 24034312
J Hepatol. 2017 Oct;67(4):739-748
pubmed: 28549917
Immunobiology. 2014 Jul;219(7):547-53
pubmed: 24721706
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Gastroenterology. 2015 Jun;148(7):1383-91.e6
pubmed: 25747273
J Vasc Interv Radiol. 2020 Jan;31(1):25-34
pubmed: 31422022
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Hepatology. 2011 Dec;54(6):2036-47
pubmed: 21898499
Nat Rev Cancer. 2018 Feb;18(2):128-134
pubmed: 29326430
J Cell Mol Med. 2021 Sep;25(18):8602-8614
pubmed: 34423899
J Biol Chem. 2005 Dec 9;280(49):40749-56
pubmed: 16230360
Oncoimmunology. 2018 May 7;7(7):e1440169
pubmed: 29900044
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Nat Rev Gastroenterol Hepatol. 2020 Dec;17(12):755-772
pubmed: 32681074
Oncol Rep. 2018 Nov;40(5):2547-2557
pubmed: 30226584
Int J Cancer. 2014 Aug 1;135(3):635-46
pubmed: 24374650
Mol Ther. 2018 Jul 5;26(7):1840-1854
pubmed: 29759938
AJR Am J Roentgenol. 2017 Aug;209(2):277-288
pubmed: 28463538
Hepatology. 2016 Mar;63(3):864-79
pubmed: 26599259
Cancers (Basel). 2019 Aug 28;11(9):
pubmed: 31466358
Oncol Rep. 2020 Feb;43(2):671-680
pubmed: 31894312
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Int J Oncol. 2012 Nov;41(5):1601-9
pubmed: 22971679
Hum Vaccin Immunother. 2016 Sep;12(9):2219-31
pubmed: 27135835
J Clin Immunol. 2014 Feb;34(2):194-203
pubmed: 24337625
PLoS One. 2010 Dec 29;5(12):e14460
pubmed: 21206745
Cancer Immunol Res. 2015 Sep;3(9):1052-62
pubmed: 25943534
Gastroenterology. 2012 Jan;142(1):119-29
pubmed: 21920465
World J Gastroenterol. 2004 Dec 15;10(24):3564-8
pubmed: 15534907
Front Pharmacol. 2020 Apr 24;11:537
pubmed: 32390854
Cancer Res. 2003 Nov 15;63(22):7563-70
pubmed: 14633667
Cancer Res. 2009 May 15;69(10):4277-85
pubmed: 19417133
J Hematol Oncol. 2019 May 29;12(1):52
pubmed: 31142330
Genes Cancer. 2018 May;9(5-6):176-189
pubmed: 30603054
J Cell Biochem. 2018 Feb;119(2):2440-2449
pubmed: 28926119
J Exp Clin Cancer Res. 2019 Nov 14;38(1):467
pubmed: 31727171
Blood. 1995 May 15;85(10):2643-53
pubmed: 7742522
Oncoimmunology. 2014 Apr 15;3:e28147
pubmed: 25340009
Int J Biochem Cell Biol. 2009 Dec;41(12):2528-37
pubmed: 19695338
Clin Pharmacol Ther. 2013 Aug;94(2):169-72
pubmed: 23872826
Oncogene. 2009 Oct 8;28(40):3526-36
pubmed: 19617899
Cell Rep. 2015 Mar 17;10(10):1692-1707
pubmed: 25772357
J Hepatol. 2015 Jun;62(6):1420-9
pubmed: 25733155
Mol Med Rep. 2019 Sep;20(3):2823-2831
pubmed: 31524233
Clin Cancer Res. 2020 Aug 1;26(15):3936-3946
pubmed: 32357963
Epigenetics. 2016 Oct 2;11(10):709-720
pubmed: 27646854
J Hepatol. 2018 Mar;68(3):526-549
pubmed: 28989095
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Drug Discov Today. 2003 May 15;8(10):430-1
pubmed: 12801788
J Hepatol. 2013 Jul;59(1):81-8
pubmed: 23466307
Hepatology. 2012 Oct;56(4):1342-51
pubmed: 22505239
Int J Mol Sci. 2018 Dec 05;19(12):
pubmed: 30563158
Hepatology. 2008 Nov;48(5):1528-39
pubmed: 18925631
Hepatology. 2016 Aug;64(2):456-72
pubmed: 26990897
Ther Adv Med Oncol. 2019 Jul 23;11:1758835919862692
pubmed: 31384311
J Hepatol. 2016 Oct;65(4):798-808
pubmed: 27212245
Apoptosis. 2016 Jan;21(1):110-9
pubmed: 26496775
Science. 1996 Mar 22;271(5256):1734-6
pubmed: 8596936
Expert Opin Drug Deliv. 2013 Jun;10(6):799-810
pubmed: 23679932